Display options
Cite
Primavera D, Manchia M, Deriu L, et al. Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study. BMJ Open. 2017;7(5):e014938doi: 10.1136/bmjopen-2016-014938.
Primavera, D., Manchia, M., Deriu, L., Tusconi, M., Collu, R., Scherma, M., Fadda, P., Fratta, W., & Carpiniello, B. (2017). Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study. BMJ open, 7(5), e014938. https://doi.org/10.1136/bmjopen-2016-014938
Primavera, Diego, et al. "Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study." BMJ open vol. 7,5 (2017): e014938. doi: https://doi.org/10.1136/bmjopen-2016-014938
Primavera D, Manchia M, Deriu L, Tusconi M, Collu R, Scherma M, Fadda P, Fratta W, Carpiniello B. Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study. BMJ Open. 2017 May 25;7(5):e014938. doi: 10.1136/bmjopen-2016-014938. PMID: 28550022; PMCID: PMC5729982.
Copy Download .nbib Format: NLM
Share it on

BMJ Open. 2017 May 25;7(5):e014938. doi: 10.1136/bmjopen-2016-014938.

Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study.

BMJ open

Diego Primavera, Mirko Manchia, Luca Deriu, Massimo Tusconi, Roberto Collu, Maria Scherma, Paola Fadda, Walter Fratta, Bernardo Carpiniello

Affiliations

  1. Section of Psychiatry, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
  2. Department of Pharmacology, Dalhousie University, Halifax, Canada.
  3. Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.
  4. Centre of Excellence 'Neurobiology of Dependence', University of Cagliari, Cagliari, Italy.

PMID: 28550022 PMCID: PMC5729982 DOI: 10.1136/bmjopen-2016-014938

Abstract

INTRODUCTION: Brain-derived neurotrophic factor (BDNF) plays a crucial role in neurodevelopment, synaptic plasticity and neuronal function and survival. Serum and plasma BDNF levels are moderately, but consistently, decreased in patients with schizophrenia (SCZ) compared with healthy controls. There is a lack of knowledge, however, on the temporal manifestation of this decline. Clinical, illness course and treatment factors might influence the variation of BDNF serum levels in patients with psychosis. In this context, we propose a longitudinal study of a cohort of SCZ and schizophrenic and schizoaffective disorder (SAD) Sardinian patients with the aim of disentangling the relationship between peripheral BDNF serum levels and changes of psychopathology, cognition and drug treatments.

METHODS AND ANALYSIS: Longitudinal assessment of BDNF in Sardinian psychotic patients (LABSP) is a 24-month observational prospective cohort study. Patients with SAD will be recruited at the Psychiatry Research Unit of the Department of Medical Science and Public Health, University of Cagliari and University of Cagliari Health Agency, Cagliari, Italy. We will collect BDNF serum levels as well as sociodemographic, psychopathological and neurocognitive measures. Structured, semistructured and self-rating assessment tools, such as the Positive and Negative Syndrome Scale for psychopathological measures and the Brief Assessment of Cognition in Schizophrenia for cognitive function, will be used.

ETHICS AND DISSEMINATION: This study protocol was approved by the University of Cagliari Health Agency Ethics Committee (NP2016/5491). The study will be conducted in accordance with the principles of good clinical practice, in the Declaration of Helsinki in compliance with the regulations. Participation will be voluntary and written informed consent will be obtained for each participant upon entry into the study. We plan to disseminate the results of our study through conference presentations and publication in international peer-reviewed journals. Access to raw data will be available in anonymised form upon request to the corresponding author.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Keywords: Antipsychotics; BDNF; Prospective study; Schizophrenia & psychotic disorders

Conflict of interest statement

Competing interests: None declared.

References

  1. Neurosci Lett. 2008 Jul 11;439(2):157-9 - PubMed
  2. Am J Psychiatry. 2005 Oct;162(10):1785-804 - PubMed
  3. Int J Neuropsychopharmacol. 2012 Mar;15(2):149-61 - PubMed
  4. Schizophr Res. 2006 Sep;86(1-3):321-2 - PubMed
  5. Ageing Res Rev. 2004 Nov;3(4):407-30 - PubMed
  6. Psychiatry Res. 2008 Nov 30;161(2):213-24 - PubMed
  7. Psychopharmacology (Berl). 2012 Jul;222(2):277-84 - PubMed
  8. Nat Neurosci. 2010 May;13(5):635-41 - PubMed
  9. Psychiatry Res. 2002 Jul 31;110(3):249-57 - PubMed
  10. J Psychiatr Res. 2006 Oct;40(7):664-8 - PubMed
  11. Neurosci Lett. 2007 Jun 8;420(1):45-8 - PubMed
  12. J Child Adolesc Psychiatr Ment Health Nurs. 1991 Oct-Dec;4(4):127-31 - PubMed
  13. Mol Endocrinol. 2001 Oct;15(10):1748-57 - PubMed
  14. J Psychiatr Res. 2012 Jan;46(1):1-11 - PubMed
  15. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):709-13 - PubMed
  16. Neuropharmacology. 1998 Dec;37(12):1553-61 - PubMed
  17. Schizophr Res. 2004 Jun 1;68(2-3):283-97 - PubMed
  18. Growth Factors. 2004 Sep;22(3):123-31 - PubMed
  19. Addiction. 2009 Feb;104(2):297-307 - PubMed
  20. Psychopharmacology (Berl). 2009 Dec;207(3):375-80 - PubMed
  21. Am J Psychiatry. 1992 Sep;149(9):1148-56 - PubMed
  22. Annu Rev Biochem. 2003;72:609-42 - PubMed
  23. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1072-7 - PubMed
  24. World Psychiatry. 2013 Jun;12(2):99-107 - PubMed
  25. Mol Psychiatry. 2014 Jul;19(7):750-1 - PubMed
  26. J Clin Psychopharmacol. 2015 Oct;35(5):596-9 - PubMed
  27. Int J Neuropsychopharmacol. 2011 Apr;14(3):347-53 - PubMed
  28. Int Clin Psychopharmacol. 2007 Jan;22(1):21-7 - PubMed
  29. Qual Life Res. 2004 Mar;13(2):299-310 - PubMed
  30. Schizophr Res. 2007 Mar;91(1-3):1-5 - PubMed
  31. J Psychiatr Res. 2007 Dec;41(12):997-1004 - PubMed
  32. J Neurosci. 2003 Jul 30;23(17):6856-65 - PubMed
  33. Am J Psychiatry. 1996 Mar;153(3):321-30 - PubMed
  34. Harv Rev Psychiatry. 2016 Mar-Apr;24(2):118-28 - PubMed
  35. Epidemiol Psichiatr Soc. 2006 Jul-Sep;15(3):228-32 - PubMed
  36. Br J Psychiatry. 2014 Aug;205(2):88-94 - PubMed
  37. Int Clin Psychopharmacol. 1995 Sep;10 Suppl 3:133-8 - PubMed
  38. Neurosci Lett. 2003 Nov 13;351(2):111-4 - PubMed
  39. Neuropsychobiology. 2010;62(2):87-90 - PubMed
  40. Acta Psychiatr Scand Suppl. 2003;(416):16-23 - PubMed
  41. Arch Psychiatr Nervenkr (1970). 1983;233(6):509-23 - PubMed
  42. Pharmacol Rev. 2012 Apr;64(2):238-58 - PubMed
  43. Schizophr Res. 2005 May 1;74(2-3):263-70 - PubMed
  44. J Psychiatr Res. 2007 Jan-Feb;41(1-2):31-5 - PubMed
  45. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1308-11 - PubMed
  46. Cell. 1999 Sep 17;98(6):739-55 - PubMed
  47. Ann Gen Psychiatry. 2015 Feb 13;14:6 - PubMed
  48. Schizophr Bull. 1982;8(3):470-84 - PubMed
  49. Schizophr Res. 2008 Jan;98(1-3):312-7 - PubMed
  50. J Clin Psychiatry. 2012 Jul;73(7):1025-33 - PubMed
  51. Schizophr Res. 2005 Jul 15;76(2-3):247-65 - PubMed
  52. Stat Med. 2012 Nov 30;31(27):3328-36 - PubMed
  53. Biol Psychiatry. 2011 Oct 1;70(7):619-25 - PubMed
  54. Schizophr Res. 2004 Dec 15;72(1):41-51 - PubMed
  55. Exp Neurol. 1995 Feb;131(2):229-38 - PubMed
  56. Mol Psychiatry. 2000 Nov;5(6):594-603 - PubMed
  57. Prog Neurobiol. 2003 Apr;69(5):341-74 - PubMed
  58. Nat Commun. 2013;4:2490 - PubMed
  59. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1508-12 - PubMed
  60. EMBO J. 1982;1(5):549-53 - PubMed
  61. Mol Psychiatry. 2015 Sep;20(9):1108-19 - PubMed
  62. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15239-44 - PubMed
  63. Neuroscience. 2009 Apr 10;159(4):1193-9 - PubMed
  64. Front Psychiatry. 2013 Jun 17;4:45 - PubMed
  65. Psychol Med. 2006 Oct;36(10):1349-62 - PubMed
  66. Int J Clin Pract. 2008 Dec;62(12):1943-6 - PubMed
  67. Ann Gen Psychiatry. 2012 Aug 02;11(1):21 - PubMed
  68. Neurosci Lett. 2005 Jul 1-8;382(1-2):27-32 - PubMed
  69. Biometrics. 2007 Sep;63(3):699-707 - PubMed
  70. Nat Rev Drug Discov. 2011 Mar;10(3):209-19 - PubMed
  71. Schizophr Bull. 1987;13(2):261-76 - PubMed
  72. Mol Psychiatry. 2005 Apr;10(4):345-52 - PubMed
  73. Psychiatry Res. 2015 Mar 30;226(1):1-13 - PubMed
  74. J Clin Exp Neuropsychol. 2006 Feb;28(2):260-9 - PubMed
  75. Schizophr Res. 2008 Apr;101(1-3):58-66 - PubMed
  76. J Psychiatr Res. 2015 Jan;60:56-64 - PubMed
  77. Biol Psychiatry. 2009 Sep 15;66(6):549-53 - PubMed
  78. J Cell Biol. 2012 Mar 19;196(6):775-88 - PubMed

Substances

MeSH terms

Publication Types